News and Events
Read about the latest news and events at Vironova.
2017 | 03 | 23
Free webinar April 6: Automated purity and integrity analysis of gene therapy vectors
Time: 3:00pm London, 10:00am New York
Key learning objectives
- How MiniTEM™ automatically images, detects and classifies viral particles in ~1h
- How the proportion of intact vs broken Adeno-associated virus (AAV) and Adenovirus in different samples can be measured accurately
- How to perform automated purity analysis of virus particle samples
2017 | 03 | 16
Open position: Research Associate / Technician
Vironova Biosafety is one of three business units within Vironova AB. We now need to strengthen our team with an additional person. We are looking for a microbiologist / biomedical scientist / biochemist with extensive experience in laboratory work. Vironova Biosafety currently consists of four people who work with virus validation studies and related tasks, as well as development work.
2017 | 03 | 15
Record turnover for NOW Electronics in its first year as a Vironova-owned company
2016 saw Mikael Wik appointed as new CEO and a record sales performance that beat all previous years, with a turnover of 25,9 MSEK. The two founders and previous leaders since 1985 continue to be active in sales and business development.
“Acquisition of NOW is of great value in strengthening our technical edge, for example in developing the camera for MiniTEM. We look forward to many more advances in the TEM technology and infrastructure” says Mohammed Homman, CEO, Vironova.
NOW continues to grow, with a focus on new recruitments. The latest addition is a female with a degree in mechanics. Moving forward, NOW will focus on long-term projects as well as the life science sector. The core business of in-house consulting will of course continue.
2017 | 03 | 02
European MiniTEM seminar; “Automated virus particle characterization”, March 30 in Leiden
Everybody with a need to speed up process development or secure final product quality of virus particle based therapeutics should attend this seminar. The event offers an opportunity to learn about Vironova’s solutions for nanoparticle characterization directly from the developers and experts.
In addition, invited speakers from key players in the gene therapeutics industry will share their thoughts on current trends and challenges associated with quality control.
Case studies on automated purity and integrity analysis of gene therapy vectors using MiniTEM will be presented. Enabling of automation will be explained through a live demonstration of the MiniTEM system.
The event will take place at Biotech Training Facility in the Bio Science Park in Leiden, Holland.
2017 | 02 | 28
Vironova AB is a partner in a Big Data and Computational Science project that has received 29 M SEK in funding from the Swedish foundation for Strategic Research.
Vironova AB is once again a participant in a cutting-edge research program, this time in a Big Data and Computational Science entitled program “Hierarchical Analysis of Temporal and Spatial Image Data.”
Transmission electron microscopy (TEM) images contain very rich information and data-volumes. This program enables valuable knowledge exchange in handling massive amounts of image data and will allow further development of the Vironova TEM-based technologies for access to a wider community. It is also an important milestone towards digital ultrapathology.
The project is headed by Professor Carolina Wählby, Uppsala University, Dept. Information Technology and Vironova is represented by CTO Ida-Maria Sintorn. Other partners are Astra Zeneca and SciLifeLab.
2017 | 02 | 23
Vironova AB signs one-year agreement with the U.S. Food and Drug Administration to beta test proprietary Vironova Analyzing Software (VAS).
In one of the fastest growing drug development areas today, nano-particles (for example liposomes), visible using electron microscopy, are used to deliver drugs to their exact targets in the body.
Proprietary Vironova Analyzing Software (VAS) in combination with Cryo-transmission electron microscopy (cryoTEM) enables semi-automated image analysis of liposomes, providing accurate, reproducible and timely results.
“Beta-testing is designed to help us accelerate development and improve the robustness and user friendliness of VAS. This is a very valuable compliment to the input from our internal microscopists who work with liposome characterization,” says Nina Ewerlöf, Head of Vironova instruments and software.
The U.S. Food and Drug Administration's National Center for Toxicological Research is a global resource for innovative scientific solutions in support of the agency’s mission to improve public health.
2017 | 02 | 16
Vironova is together with AstraZeneca part of a drug delivery technology Industrial Research Centre which has received 75M SEK from the Swedish foundation for Strategic Research (SSF).
At Vironova we are proud about being part of this new FoRmulaEx centre that has been recognized by SSF to meet the highest international scientific standards. The FoRmulaEx centre will develop methods for efficient and robust delivery of complex, oligonucleotide drugs. Our participation is an endorsement of our leading position in enabling electron microscopy technologies that help to speed up product development and secure final product quality in the pharmaceutical industry.
2017 | 01 | 03
Open position: Scientist with extensive experience in nsTEM & cryoTEM
As the demand for our services increases we need to extend our team and are looking for someone with experience in both nsTEM and cryoTEM. You will join a team of scientists focusing on timely delivery of projects to high quality to a global pool of clients.
2016 | 12 | 16
Article published in Bioprocess International
Ask the Expert article "Reveal Information That Provides Insights” in the December issue of BioProcess International.
The article features Josefina Nilsson and Gustaf Kylberg who present the benefits of using MiniTEM in purity analysis during process development.
2016 | 11 | 22
Interview in DI Digital with tech-investor Eva Redhe, shareholder in Vironova.
Eva is recognized by DI Digital as one of Sweden’s most powerful tech-investors. She has a long career in the financial sector. After 30 years in the industry, as an entrepreneur and an employee at Investor, she completed her operative career as CEO and Chairman of Erik Penser Bank in 2008.
2016 | 11 | 03
His Majesty Carl XVI Gustaf price for remarkable entrepreneurial achievements to Mohammed Homman, founder and CEO of Vironova
Mohammed receives the price as a recognition for his open minded, energetic and solution oriented approach that has resulted in positioning Vironova as a highly versatile and multicultural working place and a company that attracts top talents that delivers disruptive technology for sub-visible particle characterization. The jury describes Mohammed Homman as an important role model that proves the potential of having an open and versatile Swedish society.
2016 | 10 | 28
Vironova is moving into new facilities
Vironova is growing. There is no room for us anymore in our current place. Every week there are new additions to our team and our EM facilities are expanding in order to meet the growing demand for services as well as to be able to store and service our MiniTEM systems. We are moving to a nice, sunny and spacious place just next door in the same building that is currently being set up for us. Next week all arrangements are ready and we will move in.
2016 | 10 | 21
Future forces forum: International platform for trends & technologies in defence and security
Date: October 19-21 in Prague A Medical Workshop where Ida-Maria Sintorn presented “MiniTEM- a Broad Range Viral Pathogen Detection System” . Vironova and Delong Instruments had a joint booth at the event. You also from the image get a flavor of the field based modular labs and hospitals that are applied in the field in case of an emergent pathogen outbreak– a situation where MiniTEM could potentially be a tool.
2016 | 10 | 07
Vironova at Biotech Week in Boston
The new MiniTEM low voltage transmission electron microscope system was introduced for the first time to a larger audience at the Boston Biotech Week. A steady stream of visitors working in downstream applications covering biologics and gene therapy came to the booth to get a demonstration. Gustaf Kylberg, technical product owner was very busy explaining the automated purity analysis the system enables. The small size of the system together with the fact that it is very easy to operate generated a lot of enthusiasm and happy exclamations.
2016 | 10 | 07
Webinar: Reveal information that Gives Insights: New Approaches to Sub-Visible Particle Characterization
Date: October 19
Time: 11:00am - 11:15am EDT
In this webinar you will learn:
- How MiniTEM automatically images, detects and classifies a large number of particles resulting in statistically significant and reproducible data.
- How a metric for sample purity based on the ratio of the total area of debris to that of intact Adenovirus particles is applied.
- How analysis using MiniTEM saves about 65 hours compared with manual operation.
2016 | 10 | 07
Vironova at Biotech Week in Boston
The workshop “Reveal Information that Gives Insights – New Approaches to Sub-Visible Particle Characterization” by Gustaf together with Josefina Nilsson, head of EM services gave an in depth presentation on how to automatically acquire an accurate purity metrics as well as visual proof of Adenovirus particle samples at different steps in the purification process.
2016 | 08 | 10
Vironova workshop at Biotech Week Boston: Reveal information that Gives Insights – New Approaches to Sub-Visible Particle Characterization
Dr. Josefina Nilsson, Head of EM services and Dr. Gustaf Kylberg, Product Manager MiniTEM, Vironova AB
A case study on how to speed up time to insight during purification and formulation development. The purity of two different Adenovirus samples were compared and analyzed. Automated image acquisition and particle classification was performed using MiniTEMTM -a compact, low voltage transmission electron microscope. High quality images and accurate quantitative data were obtained in less than 4h.
Date: 6 October
Time: 12:35 pm - 1:05 pm
2016 | 07 | 04
Ask the Expert editorial in Bioprocess International
Josefina Nilsson, head of Vironova EM services, is featured in the editorial article in the June issue of Bioprocess International where she describes how electron microscopy and image analysis performed by Vironova provide all the structural information needed for effective and high-quality research, development and manufacturing of gene and drug delivery systems.
2016 | 05 | 23
ProViz: A new software for easy and intuitive visualisation and analysis of electron tomograms with low signal-to-noise ratio.
Visual understanding is a key aspect when studying electron tomography data-sets, aside quantitative assessments such as registration of high-resolution structures. In a recently published article, Vironova CTO Ida-Maria Sintorn and co-authors present the free software tool ProViz (Protein Visualization) for visualisation and template matching in electron tomograms of biological samples.
2016 | 04 | 07
VIP event attracts Life science leaders for MiniTEM sneak peak
The Vironova MiniTEM event in conjunction to the BioSpring Europe Stockholm meeting attracted more than 40 carefully selected VIP guests in leading positions from the Life Science industry. The first manufactured series of the MiniTEM microscope was presented accompanied by wine tasting in a nice atmosphere at the 33rd floor of the BioSpring conference venue.
2015 | 12 | 16
Vironova acquires NOW Electronics AB in Kista, Sweden
The acquisition of NOW is part of a long term plan of Vironova of building a strong technology platform to enable further development of electron microscopy based analysis tools for nanoparticle characterization. Vironova has together with NOW developed a camera specialized for electron microscopy use.
2015 | 11 | 27
Vironova recruits Chief Financial Officer
“We are happy to welcome Niklas Norén, our new CFO, to the Vironova team. Niklas brings extensive experience from rapidly growing listed and unlisted companies from various industries where he has gained a vast experience in introducing companies to a commercial phase as well as the capital market,” comments Mohammed Homman, Founder and CEO of Vironova AB.
Niklas’s experience from the Pharmaceutical industry includes work with Medivir and Johnson & Johnson.
2015 | 07 | 01
Vironova recruits Marketing Strategist
“We are happy to welcome Nina Forsberg, our new marketing strategist, to the Vironova team. Nina brings extensive experience from the Pharmaceutical industry where she has gained a vast experience introducing new products to the Pharmaceutical market,” comments Mohammed Homman, Founder and CEO of Vironova AB.
Nina’s experience from the Pharmaceutical industry includes work at Roche, Amersham and GE Healthcare.
Upcoming Events 2017
“Automated virus particle characterization with MiniTEM”
European MiniTEM event March 30 in Leiden
Seminar and live demo of the MiniTEM instrument
Detailed agenda and registration
7th ISBioTech Spring Meeting March 6-8 in Washington, DC
- Workshop Monday March 6, 10.30-11.00
“Characterization of viral vectors by semi-automated Electron Microscopy analysis “
Speaker: Josefina Nilsson, Head of Vironova EM services
April 6 at 3 pm
“Automated purity and integrity check of gene therapy vectors”
Speakers are Josefina Nilsson, Head of Vironova EM Services and Martin Ryner, Manager strategic development at Vironova.
Agenda and registration here.
BioProcess International (BPI ) 2017 Summit April 25-26 in Amsterdam
- Exhibition of MiniTEM
- Oral Tuesday April 25, 3.00 - 3.30 pm
“Characterization of gene therapy vectors, VLPs and whole viruses from pre-formulation through process development to final manufacturing”
Speaker: Josefina Nilsson, Head of Vironova EM services
Bioprocess International & Cell and gene therapy bioprocessing September 25-28 in Boston
- Exhibition of MiniTEM
- Technology workshop (title and speaker to be confirmed)
Vironova on MyNewsDesk
Follow us on MyNewsDesk and get the latest info on investor relations, events and company news. Click here to get to our MyNewsDesk-page.
For press enquiries, please contact